Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma

Studies have shown that using Castle’s DecisionDx^®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes^1-5

Castle’s management team will also ring the New York Stock Exchange closing bell on Sept. 28 as a member of the Texas Capital Texas Equity Index exchange traded fund (ETF)

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company will ring the Nasdaq closing bell on Wednesday, Sept. 27, 2023, to raise awareness of melanoma in honor of patients impacted by the disease.

“Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member. “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care. At the end of the day, we are all working together to make an impact in people’s lives and perhaps provide something even more powerful than that … hope for the future.”

Melanoma will claim nearly 20 American lives each day this year, making it the most aggressive form of skin cancer.⁶ Castle’s DecisionDx-Melanoma test is designed to provide personalized information about a patient’s risk of melanoma recurrence, metastasis and sentinel lymph node positivity based on the biology of their tumor. This information can inform important decisions regarding a patient’s treatment and follow-up care that have been shown to improve health outcomes.^1-5

Along with Castle’s leadership team at the Nasdaq closing bell ceremony will be the following:

• Darrell Rigel, M.D., M.S., dermatologist, leading melanoma expert and clinical professor of dermatology at the Mount Sinai Icahn School of Medicine in New York. Rigel is also the co-creator of the ABCDEs of early melanoma detection, a standard in today’s dermatologic practice designed to help the public and clinicians identify features of suspicious skin lesions.
• Ed Dobbles, D.B.A., IMPACT Melanoma board member. IMPACT Melanoma is the nation’s leading non-profit dedicated to significantly reducing the incidence of melanoma in the United States and saving lives.

The live broadcast will begin at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York. To view the broadcast, use this link: https://livestream.com/accounts/888332/events/10948952.

The following day, Thursday, Sept. 28, Maetzold and Frank Stokes, chief financial officer, will join special guest Texas Gov. Greg Abbott and other members of the Texas Capital Texas Equity Index exchange traded fund (ETF) to ring the closing bell at the New York Stock Exchange to celebrate the fund’s launch. The ETF is comprised of 215 publicly listed companies headquartered in Texas and is designed to reflect the performance of a diversified group of companies having a material impact on the state’s economy.

About DecisionDx^®-Melanoma

DecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by more than 40 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through June 30, 2023, DecisionDx-Melanoma has been ordered more than 137,200 times for patients diagnosed with cutaneous melanoma. More information about the test and disease can be found at www.CastleTestInfo.com.

About IMPACT Melanoma

IMPACT Melanoma, a national non-profit 501(c)(3) organization, is the nation’s leading non-profit dedicated to significantly reducing the incidence of melanoma in the United States and saving lives. The organization focuses on prevention education programs that include customized and integrated programs for communities. In addition to skin cancer prevention education and programs, IMPACT Melanoma is committed to supporting melanoma patients and their families and influencing urban development policies to address shade equity in America. To learn more about IMPACT Melanoma, visit https://impactmelanoma.org/.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the potential of DecisionDx-Melanoma to inform important decisions regarding a melanoma patient’s treatment and follow-up care and help guide patient care and improve health outcomes. The words “can,” “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings, including with respect to DecisionDx-Melanoma; actual application of our DecisionDx-Melanoma test may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, our Quarterly Report on Form 10-Q for the three months ended June 30, 2023, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

1. Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. JCO Precis. Oncol. 2023; 7. doi: 10.1200/PO.23.00044
2. Dhillon S, Duarte-Bateman D, Fowler G, et al. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Arch Dermatol Res. 2023. https://doi.org/10.1007/s00403-023-02613-6.
3. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207-1217. doi: 10.2217/fon-2018-0912
4. Whitman ED, Koshenkov VP, Gastman BR, et al. Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. JCO Precis. Oncol. 2021; 5: 1466-1479. doi: 10.1200/PO.21.00162
5. Yamamoto M, Sickle-Santanello B, Beard T, et al. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. Curr. Med. Res. Opin. 2023;39(3): 417-423. doi: 10.1080/03007995.2023.2165813
6. American Academy of Dermatology; https://www.aad.org/media/stats-skin-cancer; accessed Sept. 11, 2023

View source version on businesswire.com: https://www.businesswire.com/news/home/20230925508868/en/